Articles

Checkpoint Inhibitor Therapy for Metastatic Triple-Negative Breast Cancer

Along with surgery, radiation, chemotherapy, and targeted therapy, immunotherapy has emerged as the fifth pillar of cancer treatment and is revolutionizing cancer treatment across the board. Read More ›

Patient-Reported Outcomes from a Phase 3 Trial in Premenopausal Patients with ER-Positive, HER2-Negative, Lymph Node–Positive Breast Cancer

Treatment with ICIs in metastatic TNBC has shown encouraging results. Immunotherapy has shifted the paradigm of cancer treatment and opened new research opportunities. TNBC is characterized by immunologic activation while being the most common subtype of breast cancer. Read More ›

Updates on Endocrine Therapy for Metastatic Breast Cancer

Neoadjuvant chemotherapy is becoming more popular for patients with locally advanced breast cancer. Downstaging may result in a smaller surgical extent or a higher breast conservation rate, and a better cosmetic outcome. Chemotherapy, on the other hand, has both short- and long-term complications. Read More ›

Effectiveness of Alpelisib plus Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR-Positive, HER2-Negative, PIK3CA Mutation–Positive Breast Cancer

Endocrine therapy used in combination with CDK4/6 inhibitors, in particular, have transformed the metastatic breast cancer landscape, promisingly improving progression-free survival and overall survival among patients with HR-positive, HER2-negative metastatic breast cancer. Read More ›

Minimal Activity with Sapanisertib in Refractory Renal-Cell Carcinoma

The therapeutic advantage of alpelisib over fulvestrant in the treatment of patients with HR-positive, HER2-negative breast cancer and other malignancies is further enhanced by a matched/weighted analysis comparing BYLieve with the real-world scenario. Read More ›

Active Therapy Improves Survival versus BSC After Disease Progression on Nivolumab and Cabozantinib

In a phase 2 study, sapanisertib did not improve outcomes in renal-cell carcinoma. Read More ›

Real-World Treatment Patterns Have Drastically Changed Over the Past 5 Years

In a retrospective study, active therapy conferred a survival benefit versus BSC for patients who have disease progression on both nivolumab and cabozantinib. Read More ›

Functional Imaging Predicts Outcomes in Patients Treated with Antiangiogenic Therapy

Since the approval of dual immune checkpoint inhibition, real-world treatment patterns have evolved. Read More ›